When patients and healthcare assistants look for Braftovi price in India, they seek a couple of things:
- clarity on stock availability, and
- a legal method to obtain the medicine
Braftovi (encorafenib) is a targeted therapy drug. It is approved in several markets across the world, but it is not yet approved for marketing in India. For this reason, Braftovi in India is available only as an imported drug. It is only available as per the Named Patient Program (NPP) as per Indian regulations.
Is Braftovi Available in India?
For now, Braftovi availability in India is limited and can only be accessed through a named patient import request. This medicine can neither be acquired through conventional chain pharmacies nor through normal pharmacy procurement from hospitals.
This means:
- There are no Indian pharmacies that sell Braftovi
- No one can buy it as a routine domestic product
- It must be obtained as a personal import on a named patient basis
- A valid medical prescription and medical justification are required
Without a doubt, this process guarantees adherence to all local, national, and international regulations.
Braftovi Price in India – What Determines the Cost?
The Braftovi price in India differs for patients. Below are reasons for that:
- Country of origin and manufacturer pricing
- Dosage strength and duration of treatment
- Customs duties and import documentation
- International freight and cold-chain handling
- Exchange rates at the time of import
As Braftovi is an imported oncology medicine, there is no fixed MRP in India. Final pricing is done upon import, based on the individual needs of the patient.
As a result, it is preferable for patients to receive an individualized quotation instead of depending on average pricing.
How to Buy Braftovi in India Through Legal Channels?
If you want to buy Braftovi in India, you should adhere to the Named Patient Program (NPP) clause, as it is allowed by the Indian law regarding drug importation.
The steps in the process usually include the following:
- Prescription from a treating oncologist
- Medical justification explaining the clinical need
- Patient consent and identification documents
- Import application under the Named Patient Program
- One-time import specifically for the named patient
This guarantees legal access to imported prescription medicines like Braftovi in India.
Braftovi Import in India – Regulatory Clarity
Braftovi imports in India are regulated under the Drugs & Cosmetics Act, and unapproved unlicensed medicines via the CDSCO.
Key points:
- Import is patient-specific, not commercial
- Each shipment is tied to one named patient
- Quality, batch traceability, and documentation are mandatory
- The medicine is supplied only against a doctor’s prescription
This pathway is popular for advanced oncology and other rare disease medicines not yet available in the market.
Why Patients Rely on Indian Pharma Network for Braftovi Access?
The Indian Pharma Network (IPN) helps patients, hospitals, and doctors deal with the complexities of getting Braftovi through the Named Patient Program in India.
IPN offers the following assistance:
- Help with documentation and compliance
- Coordination with international suppliers
- Transparent quotation for Braftovi price in India
- End-to-end assistance until delivery
The focus is not on retail sales, but on compliance with regulations, access to care in a timely manner, and most importantly, on patient safety.
Important Note for Patients and Caregivers:
Braftovi must only be used:
- When prescribed by a licensed oncologist
- Under proper medical supervision
- After confirming eligibility through diagnostic testing
Treatment decisions must be at the sole discretion of the physician in charge of the case.
Conclusion:
For those who want to know the Braftovi price in India, it is important to understand that Braftovi is not a general medicine. It is an imported drug that can be made available only through the provision called the Named Patient Program (NPP).
With the right medical documentation and a compliant import partner, Braftovi availability in India can be arranged through legal channels—helping patients access advanced therapy when local options are limited.
Disclaimer: This content is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Braftovi (encorafenib) should be used strictly under the supervision of a qualified oncologist and only after appropriate diagnostic confirmation.
References:
- U.S. Food and Drug Administration (FDA) – Encorafenib (Braftovi) Prescribing Information
- European Medicines Agency (EMA) – Braftovi (encorafenib) – EPAR Product Information
- National Comprehensive Cancer Network (NCCN) – NCCN Clinical Practice Guidelines in Oncology (Melanoma, Colorectal Cancer, NSCLC)
- Central Drugs Standard Control Organization (CDSCO), India – Import of Unapproved / New Drugs under Named Patient Basis
- Drugs & Cosmetics Act, 1940 and Rules, 1945 (India) – Legal framework governing import of unapproved medicines
- World Health Organization (WHO) – Access to Medicines and Patient-Centric Import Pathways
